A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer s Disease.

8385BAN2401-G000-301OpenA Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer s Disease.NCT03887455IndustrialAdultTreatmentIIIDiseases Of The Nervous SystemTurner, RaymondGeorgetown University Medical Center : Ava Wagner; Lombardi Comprehensive Cancer Center : Ava WagnerGUMC Neurology; GUMC PFS16711Ava WagnerAva Wagneraw1448@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>